Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deborah Rudin

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
Frontiers in Genetics|September 25, 2020
High-Throughput Sequencing to Investigate Associations Between HLA Genes and Metamizole-Induced AgranulocytosisAnca Liliana Cismaru, Livia Grimm, Deborah Rudin, et al.
Frontiers in Pharmacology|May 14, 2024
<i>In vitro</i> and <i>in vivo</i> metabolism of psilocybin's active metabolite psilocinJan Thomann, Karolina E Kolaczynska, Oliver V Stoeckmann, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|December 20, 2024
Acute dose-dependent effects and self-guided titration of continuous N,N-dimethyltryptamine infusions in a double-blind placebo-controlled study in healthy participantsLivio Erne, Severin B Vogt, Lorenz Müller, et al.
Endocrine Connections|April 27, 2026
Neurophysin-I dynamics upon different pituitary provocation tests in healthy participantsAndi Nikaj, Cihan Atila, Deborah Rudin, et al.
Neuropharmacology|April 17, 2021
α-PPP and its derivatives are selective partial releasers at the human norepinephrine transporter: A pharmacological characterization of interactions between pyrrolidinopropiophenones and high and low affinity monoamine transportersJulian Maier, Laurin Rauter, Deborah Rudin, et al.
Biochemical Pharmacology|February 14, 2026
Ibogalogs induce antiseizure activity in rodents by a mechanism involving 5-HT<sub>2A/2C</sub> receptor activation with a major role of 5-HT<sub>2A</sub> receptors in the hippocampal CA3 subfieldAbdeslam Chagraoui, Paulina Kazmierska-Grebowska, Olivia Byache, et al.
RSC Medicinal Chemistry|August 6, 2021
Illuminating the norepinephrine transporter: fluorescent probes based on nisoxetine and talopramGisela Andrea Camacho-Hernandez, Andrea Casiraghi, Deborah Rudin, et al.
European Journal of Pharmacology|January 22, 2024
The novel non-hallucinogenic compound DM506 (3-methyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole) induces sedative- and anxiolytic-like activity in mice by a mechanism involving 5-HT<sub>2A</sub> receptor activationHugo R Arias, Deborah Rudin, Dustin J Hines, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|June 18, 2024
Non-hallucinogenic compounds derived from iboga alkaloids alleviate neuropathic and visceral pain in mice through a mechanism involving 5-HT<sub>2A</sub> receptor activationHugo R Arias, Laura Micheli, Deborah Rudin, et al.
NPJ Vaccines|February 24, 2022
The feasibility of pragmatic influenza vaccine randomized controlled real-world trials in Denmark and EnglandJoshua Nealon, Daniel Modin, Rebecca E Ghosh, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Frontiers in Genetics|September 25, 2020
High-Throughput Sequencing to Investigate Associations Between HLA Genes and Metamizole-Induced AgranulocytosisAnca Liliana Cismaru, Livia Grimm, Deborah Rudin, et al.
Frontiers in Pharmacology|May 14, 2024
<i>In vitro</i> and <i>in vivo</i> metabolism of psilocybin's active metabolite psilocinJan Thomann, Karolina E Kolaczynska, Oliver V Stoeckmann, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|December 20, 2024
Acute dose-dependent effects and self-guided titration of continuous N,N-dimethyltryptamine infusions in a double-blind placebo-controlled study in healthy participantsLivio Erne, Severin B Vogt, Lorenz Müller, et al.
Endocrine Connections|April 27, 2026
Neurophysin-I dynamics upon different pituitary provocation tests in healthy participantsAndi Nikaj, Cihan Atila, Deborah Rudin, et al.
Neuropharmacology|April 17, 2021
α-PPP and its derivatives are selective partial releasers at the human norepinephrine transporter: A pharmacological characterization of interactions between pyrrolidinopropiophenones and high and low affinity monoamine transportersJulian Maier, Laurin Rauter, Deborah Rudin, et al.
Biochemical Pharmacology|February 14, 2026
Ibogalogs induce antiseizure activity in rodents by a mechanism involving 5-HT<sub>2A/2C</sub> receptor activation with a major role of 5-HT<sub>2A</sub> receptors in the hippocampal CA3 subfieldAbdeslam Chagraoui, Paulina Kazmierska-Grebowska, Olivia Byache, et al.
RSC Medicinal Chemistry|August 6, 2021
Illuminating the norepinephrine transporter: fluorescent probes based on nisoxetine and talopramGisela Andrea Camacho-Hernandez, Andrea Casiraghi, Deborah Rudin, et al.
European Journal of Pharmacology|January 22, 2024
The novel non-hallucinogenic compound DM506 (3-methyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole) induces sedative- and anxiolytic-like activity in mice by a mechanism involving 5-HT<sub>2A</sub> receptor activationHugo R Arias, Deborah Rudin, Dustin J Hines, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|June 18, 2024
Non-hallucinogenic compounds derived from iboga alkaloids alleviate neuropathic and visceral pain in mice through a mechanism involving 5-HT<sub>2A</sub> receptor activationHugo R Arias, Laura Micheli, Deborah Rudin, et al.
NPJ Vaccines|February 24, 2022
The feasibility of pragmatic influenza vaccine randomized controlled real-world trials in Denmark and EnglandJoshua Nealon, Daniel Modin, Rebecca E Ghosh, et al.
Pageof 5